Xalkori or Crizalk
Xalkori (Crizotinib) - Comprehensive Product Description
Xalkori, known generically as Crizotinib, is an oral medication used primarily for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It is a targeted therapy that works by inhibiting the activity of ALK, thereby blocking the growth and spread of cancer cells.
Indications
Xalkori is indicated for the treatment of adults with:
- ALK-positive metastatic NSCLC
- ROS1-positive metastatic NSCLC
Dosage and Administration
The recommended dosage of Xalkori is 250 mg taken orally twice daily. It can be taken with or without food. Patients should swallow the capsules whole and not chew, crush, or open them.
Mechanism of Action
Crizotinib is a small molecule inhibitor that selectively targets ALK and ROS1, two proteins involved in the growth of cancer cells. By inhibiting these proteins, Xalkori effectively disrupts the signaling pathways that promote tumor growth and survival.
Side Effects
Common side effects associated with Xalkori include:
- Nausea
- Diarrhea
- Fatigue
- Vision changes
- Constipation
Serious side effects may include liver problems, interstitial lung disease, and severe allergic reactions. Regular monitoring by a healthcare professional is recommended.
Drug Interactions
Xalkori may interact with various medications, including:
- CYP3A inhibitors and inducers
- Antiepileptic drugs
- Antifungal medications
Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.
Storage
Store Xalkori at room temperature, away from moisture and heat. Keep it out of reach of children.
Conclusion
Xalkori represents a significant advancement in the targeted treatment of ALK-positive NSCLC. Patients should consult their healthcare provider for more information and to determine if Xalkori is the right treatment option for their specific condition.
